- The Head of the Food and Drug Supervisory Agency (Badan Pengawas Obat dan Makanan – “BPOM”) has issued Decree No. 364/2024 on the List of Specified Generic Drugs Requiring Bioequivalence Testing (“Decree 364/2024”), which came into force on 3 October 2024. The promulgation of Decree 364/2024 has now rendered the previous framework of Decree No. 65/2022 invalid.
- Decree 364/2024 comprehensively outlines the various types of generic drugs that are required to undergo bioequivalence trials, as listed under the Appendix to Decree No. 364/2024. This list includes: 1) Respiratory drugs; 2) Diabetes drugs; 3) Nonsteroidal anti-inflammatories; 4) Immunosuppressants; 5) Antithrombotics; 6) Cardiovascular drugs; 7) Hormones; 8) Urinary tract drugs; 9) Systemic anti-infectives; 10) Osteoporosis drugs; 11) Central nervous system drugs; 12) Rheumatic and gout drugs; 13) Drugs to treat anemia and other blood disorders; 14) Antineoplastic and immunomodulating agents; 15) Neuromuscular disorder drugs; 16) Other therapies; and 17) Drugs with modified-release dosage forms.
- Furthermore, when conducting bioequivalence trials, applicants must submit documentation approving the bioequivalence trials for the specified generic drugs to the Head of BPOM at the time that their registrations are submitted. It is important to note that the resulting bioequivalence trial reports must be submitted by a deadline of 2 June 2027.
......
Subscribe to read more legal analysis.
Hukumonline Pro Intelligence
Platform AI hukum terpercaya sebagai solusi komprehensif riset Anda
*Syarat dan ketentuan berlaku